Clinical trials /

Atezolizumab with Bevacizumab in MRD-GI

Active, not recruitingPhase 3InterventionalNCT05482516 ↗

This is a Phase II trial studying atezolizumab and bevacizumab in ctDNA positive colorectal cancer patients with no evidence of cancer on imaging after completing standard therapies.

Sponsor
Georgetown University
Planned enrollment
11 participants
Start date
March 29, 2023
Primary completion
August 20, 2026 (est.)
Minimum age
18 Years
Interventions
Atezolizumab, Bevacizumab

Official title: Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD–GI)

This study is a non-randomized, multi-site, pilot feasibility therapeutic trial that will enroll 20 patients diagnosed with histologically confirmed GI cancers, including colorectal.

Key Eligibility Criteria

  • Diagnosis of any stage (I-IV) colorectal adenocarcinoma
  • Completion of all curative-intent treatments
  • Documented disease-free status by physical exam and no evidence of disease on standard imaging within 28 days of enrollment
  • Positive ctDNA test result (Signatera) within 1 year of completing all curative-intent treatment and within 28 days of enrollment

Visit and treatment details

Therapeutic agents

Click the drug name for more information.

Atezolizumab

Bevacizumab

More Information

Click the below link for more information.

ClinicalTrials.gov

Where this trial is offered

  • Georgetown Lombardi Comprehensive Cancer CenterWashington D.C., District of Columbia

Status, sites, and study facts from ClinicalTrials.gov, last posted October 6, 2026 and refreshed here November 2, 2026.View the full record for NCT05482516.